Immune Response to the COVID-19 Vaccine
Who is this study for? Adult patients with cancer who have had COVID-19 vaccine
What treatments are being studied? SARS-COV2 Pfizer Vaccine
Status: Completed
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
Explore the effects on immune response to include a potential third vaccine for the cancer cohort.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients must have active solid tumor malignancy diagnosis
• On active chemotherapy
• Received two prior SARS-COV2 Pfizer vaccines
• Age ≥ 18 years
• Ability to understand and the willingness to sign a written informed consent
• Agree to comply with study procedures
• Subjects previously enrolled under the main study
Locations
United States
Arizona
University of Arizona
Tucson
Time Frame
Start Date: 2021-06-07
Completion Date: 2022-05-08
Participants
Target number of participants: 20
Treatments
Experimental: 3rd COVID-19 vaccine (2nd booster)
Patients who were a part of the non-interventional portion of the study are eligible to receive a third COVID-19 Pfizer vaccine.
Authors
Related Therapeutic Areas
Sponsors
Leads: University of Arizona